167 related articles for article (PubMed ID: 20026388)
1. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo.
Huang R; Ke W; Han L; Liu Y; Shao K; Jiang C; Pei Y
Brain Res Bull; 2010 Apr; 81(6):600-4. PubMed ID: 20026388
[TBL] [Abstract][Full Text] [Related]
2. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles.
Huang R; Ke W; Han L; Liu Y; Shao K; Ye L; Lou J; Jiang C; Pei Y
J Cereb Blood Flow Metab; 2009 Dec; 29(12):1914-23. PubMed ID: 19654588
[TBL] [Abstract][Full Text] [Related]
3. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.
Ke W; Shao K; Huang R; Han L; Liu Y; Li J; Kuang Y; Ye L; Lou J; Jiang C
Biomaterials; 2009 Dec; 30(36):6976-85. PubMed ID: 19765819
[TBL] [Abstract][Full Text] [Related]
4. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles.
Liu Y; Huang R; Han L; Ke W; Shao K; Ye L; Lou J; Jiang C
Biomaterials; 2009 Sep; 30(25):4195-202. PubMed ID: 19467700
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model.
Huang R; Ke W; Liu Y; Wu D; Feng L; Jiang C; Pei Y
J Neurol Sci; 2010 Mar; 290(1-2):123-30. PubMed ID: 19909981
[TBL] [Abstract][Full Text] [Related]
6. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.
Huang R; Han L; Li J; Ren F; Ke W; Jiang C; Pei Y
J Gene Med; 2009 Sep; 11(9):754-63. PubMed ID: 19554623
[TBL] [Abstract][Full Text] [Related]
8. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain.
Huang R; Ke W; Liu Y; Jiang C; Pei Y
Biomaterials; 2008 Jan; 29(2):238-46. PubMed ID: 17935779
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration.
Huang R; Ke W; Han L; Li J; Liu S; Jiang C
Biomaterials; 2011 Mar; 32(9):2399-406. PubMed ID: 21185076
[TBL] [Abstract][Full Text] [Related]
10. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas.
Su Z; Xing L; Chen Y; Xu Y; Yang F; Zhang C; Ping Q; Xiao Y
Mol Pharm; 2014 Jun; 11(6):1823-34. PubMed ID: 24779677
[TBL] [Abstract][Full Text] [Related]
11. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
12. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles.
Kuo YC; Chen YC
Int J Pharm; 2015 Feb; 479(1):138-49. PubMed ID: 25560309
[TBL] [Abstract][Full Text] [Related]
13. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery.
Chen H; Tang L; Qin Y; Yin Y; Tang J; Tang W; Sun X; Zhang Z; Liu J; He Q
Eur J Pharm Sci; 2010 May; 40(2):94-102. PubMed ID: 20298779
[TBL] [Abstract][Full Text] [Related]
14. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.
Huang S; Li J; Han L; Liu S; Ma H; Huang R; Jiang C
Biomaterials; 2011 Oct; 32(28):6832-8. PubMed ID: 21700333
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy.
Miao D; Jiang M; Liu Z; Gu G; Hu Q; Kang T; Song Q; Yao L; Li W; Gao X; Sun M; Chen J
Mol Pharm; 2014 Jan; 11(1):90-101. PubMed ID: 24295590
[TBL] [Abstract][Full Text] [Related]
17. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study.
Zheng F; Shi XW; Yang GF; Gong LL; Yuan HY; Cui YJ; Wang Y; Du YM; Li Y
Life Sci; 2007 Jan; 80(4):388-96. PubMed ID: 17074366
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and brain uptake of lactoferrin in rats.
Ji B; Maeda J; Higuchi M; Inoue K; Akita H; Harashima H; Suhara T
Life Sci; 2006 Jan; 78(8):851-5. PubMed ID: 16165165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
